SCHEMBL2518271

SCHEMBL2518271

Cc1ccc(NC(=NO)c2nonc2N)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.45
IDO1 P14902 7/20 0.44
TDO2 P48775 1/20 0.44
HTT P42858 3/20 0.43
GFER P55789 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KIT P10721 1/20 0.42
KDR P35968 1/20 0.42
FLT3 P36888 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2518268 1.00 ALDH1A1 (0.46) ALDH1A1LMNAIDO1TDO2HTT
SCHEMBL12230806 0.90 LMNA (0.48) ALDH1A1LMNAIDO1TDO2HTT
SCHEMBL2519338 0.90 ALDH1A1 (0.46) ALDH1A1LMNAIDO1TDO2HTT
SCHEMBL2519337 0.90 ALDH1A1 (0.46) ALDH1A1LMNAIDO1TDO2HTT
SCHEMBL2514019 0.88 ALDH1A1 (0.57) ALDH1A1LMNAIDO1HTTGFER
SCHEMBL2514018 0.88 ALDH1A1 (0.57) ALDH1A1LMNAIDO1HTTGFER
SCHEMBL21118334 0.88 IDO1 (0.47) LMNAIDO1TDO2HTTGFER
SCHEMBL2520576 0.88 IDO1 (0.47) LMNAIDO1TDO2HTTGFER
SCHEMBL2520573 0.88 IDO1 (0.47) LMNAIDO1TDO2HTTGFER
SCHEMBL19661036 0.85 IDO1 (0.44) LMNAIDO1TDO2HTTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3085697-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Holdings Corporation (US) 2016-10-26 EP claimed
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2014-12-25 US claimed
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2013-05-16 US claimed
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION, A DELAWARE CORPORATION 2011-12-22 US claimed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 US claimed
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2021-12-07 US disclosed
US-20190210985-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2019-07-11 US disclosed
US-10208002-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2019-02-19 US disclosed
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2018-02-01 US disclosed
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2018-02-01 US disclosed
EP-3085697-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Holdings Corporation (US) 2016-10-26 EP disclosed
EP-3085697-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Holdings Corporation (US) 2016-10-26 EP disclosed
US-8372870-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer INCYTE CORPORATION (US) 2013-02-12 US disclosed
US-8372870-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer INCYTE CORPORATION (US) 2013-02-12 US disclosed
EP-1879573-B1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORP (US) 2012-12-19 EP disclosed
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION, A DELAWARE CORPORATION 2011-12-22 US disclosed
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION, A DELAWARE CORPORATION 2011-12-22 US disclosed
US-8034953-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2011-10-11 US disclosed
US-8034953-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2011-10-11 US disclosed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208002-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-20190210985-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT ALDH1A1 902/4885LMNA 4866/4885IDO1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.